Cognitive Longevity

Our mission is to monitor brain health and personalise therapeutic interventions

ESYA FOR ALZHEIMER'S and Parkinson's

We combine patented intracellular multi-omics analytics using DNA nanoprobes and AI to diagnose Neurodegenerative diseases before symptoms manifest.

We combine patented intracellular analytics using DNA nanoprobes with AI to diagnose neurodegenerative diseases before symptoms manifest.

white image of
ESYA FOR ALZHEIMER'S

We Develop Early, Precise, And Cost-Effective Diagnostic Tools For Neurodegenerative Diseases

We combine patented intracellular analytics using DNA nanoprobes with AI to diagnose before symptoms manifest.

black and white

We use patented DNA nanotechnology

A paradigm shift in understanding how Alzheimer’s and Parkinson’s diseases manifests opens up a whole new way of diagnosing, treating and managing the disease.

We Use Patented DNA Nanotechnology

A paradigm shift in understanding how Alzheimer’s disease manifests opens up a whole new way of diagnosing, treating and managing the disease. We combine patented Intracellular Analytics with the use of DNA Nanoprobes and AI to diagnose Alzheimer’s desease before the symptoms manifest.

colored image of

Voltair

DNA-based sensor for absolute membrane potential of cell and organelle membranes. Relevant to various neurological diseases, hypokalemia, or hyperkalemia

ca illustration drawing

CalipHluor

DNA-based, ratiometric combination reporter of pH and Ca2+. Relevant to Alzheimer’s disease, Pakinson's disease and Kufor Rakeb syndrome.

ci illustration drawing

Clensor

pH-independent, ratiometric Cl- sensor, single colour, multiplexing enabled. Relevant to Lysosomal storage disorders and Niemann Pick.

close up image

NOckout

DNA-based ratiometric NO sensitive probes. Relevant to cancer, autoimmune disease, sepsis and trauma, and vascular disease.

two medical scientists
Our Assays

Accelerate Drug Development

Our ratio-metric assays are exceptional in their ability to quantify the key chemicals within endosomes (early, recycling, and late), lysosomes, and the golgi. They can be used to complement drug discovery and patient stratification, as well as assess drug efficacy as an end point in clinical trials for lysosomal storage disorders and numerous neurocognitive impairments.

Passion is what drives us

We use DNA nanoprobes with AI to diagnose before symptoms manifest

Our Mission

A 360° Perspective For Alzheimer's Disease

We are a start-up originally spun out of Dr. Yamuna Krishnan’s lab at the University of Chicago, now based across London, UK and the U.S.

Get in touch to discuss how our probes can help you with your work .

Let's discuss now
Get In Touch With Us

If You Crave Challenges, There’s No Better Place To Be

Esya is a dynamic company operating at the intersection of biochemistry, technology, and medicine. ​If you crave challenges and the chance to see your work impact the millions of lives touched by Alzheimer’s disease, there’s no better place to be.